Primary biliary cholangitis: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

• All targets
• PPAR 0
• TLR4 0
• AKT 0
• ERK 0
• GLP-1 0
• JAK 0
• JNK 0
• MDM2 0
• mTOR 0
• NLRP3 0
• PCSK9 0
• PD-1 0
• RUNX1 0
• STING 0
• TP53 0
• YAP 0

EU-13 is a filter, not a ranking: it only narrows the list.

24 of 291 institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  TruGraf Liver Gene Expression Serial Test

  NCT06061341· Washington University School of Medicine· Updated 7 Aug 2026

  “Funding discontinued”Registry text, quoted unchanged. Source

• Terminated

  To Evaluate Safety and Tolerability of the Fixed- Dose Combination of Obeticholic Acid and Bezafibrate

  NCT06488911· Intercept Pharmaceuticals· Updated 8 Jun 2026

  “Intercept made a business decision to terminate the study based on FDA's request for voluntary withdrawal of Ocaliva and the issuance of clinical hold on studies under US IND involving OCA.”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• Study of Elafibranor in Patients With Primary Biliary Cholangitis (PBC)

  NCT04526665· Ipsen· Source

• A Study of Fatigue, Itching and Daily Activities in People With Primary Biliary Cholangitis Starting Elafibranor

  NCT07906639· Ipsen· Source

• Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford

  NCT01793168· Sanford Health· Source

• Elafibranor Pregnancy Surveillance Program: A Study to Evaluate the Safety of Elafibranor During Pregnancy

  NCT07556913· Ipsen· Source

• A Study Observing Everyday Effectiveness and Safety of the Drug Elafibranor in Participants With Primary Biliary Cholangitis Who Are Receiving Ongoing Treatment

  NCT06447168· Ipsen· Source

• A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary Cholangitis

  NCT06016842· Ipsen· Source

• A Study of Elafibranor in Adult Japanese Participants With Primary Biliary Cholangitis (PBC)

  NCT06730061· Ipsen· Source

• Study to Evaluate the Efficacy and Safety of K-808 (Pemafibrate) in Participants With Primary Biliary Cholangitis (PBC) With Inadequate Response to Ursodeoxycholic Acid (UDCA) and/or Obeticholic Acid (OCA) Treatment.

  NCT06247735· Kowa Research Institute, Inc.· Source

• J-LINX: Japan LINerixibat eXtension Study

  NCT07860710· GlaxoSmithKline· Source

• Phase I/II Trial of Human Umbilical Cord Mesenchymal Stromal Cells for UDCA-Refractory Primary Biliary Cholangitis

  NCT07795151· Beijing 302 Hospital· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 1
• Organoids 1
• Mendelian Randomization Analysis 16
• Gene Expression Profiling 5
• Proteomics 5
• Metabolomics 4
• Mass Spectrometry 1
• Flow Cytometry 2
• Immunohistochemistry 3
• Liquid Biopsy 1
• Magnetic Resonance Imaging 3
• Machine Learning 4
• Cohort Studies 7
• Genome-Wide Association Study 17

• Integrative bioinformatics analysis identifies gut microbiota-derived metabolite-associated immune candidate targets in high-risk primary biliary cholangitis.

  PLoS One, Aug 2026

• Mechanisms linking primary biliary cholangitis and osteoporosis: A combined clinical and molecular analysis.

  Medicine (Baltimore), May 2026

• Primary biliary cirrhosis and rheumatoid arthritis: a comprehensive study combining genetics and transcriptomics.

  Mamm Genome, Apr 2026

• Ubiquitin D Correlates with Disease Severity and T Cell Infiltration in Cholestasis: Evidence from Integrated Bioinformatics and Experimental Analyses.

  Int J Med Sci, Jan 2026

• Identification of Differentially Expressed Genes and Molecular Pathways Involved in Primary Biliary Cholangitis Using RNA-Seq.

  Genes (Basel), Dec 2025

See which targets of this disease your abstract mentions, and go to the people working on them.